Results 11 to 20 of about 2,141 (223)

Update of the Swiss guidelines on post-treatment Lyme disease syndrome [PDF]

Swiss Medical Weekly, 2016
Lyme borreliosis is caused by Borrelia burgdorferi sensu lato infection, which responds well to antibiotic therapy in the overwhelming majority of cases.
Johannes Nemeth, Enos Bernasconi, Ulrich Heininger, Mohamed Abbas, David Nadal, Carol Strahm, Stefan Erb, Stefan Zimmerli, Hansjakob Furrer, Julie Delaloye, Thierry Kuntzer, Ekkehard Altpeter, Mathias Sturzenegger, Rainer Weber, for the Swiss Society for Infectious Diseases and the Swiss Society for Neurology   +14 more
doaj   +5 more sources

Evaluation of immunoreactive epitopes in the sera and cerebrospinal fluid of patients with post-treatment Lyme disease syndrome [PDF]

Scientific Reports
While most patients fully recover after treatment for Lyme disease with recommended antibiotic regimens, some report non-specific symptoms after treatment. When these symptoms are unexplained by other conditions and persist for ≥ 6 months, this condition
Adriana R. Marques, Santiago Sanchez-Vicente, Akash Nagapurkar, Aleah Eschman, Siu Ping Ng, W. Ian Lipkin, Rafal Tokarz   +6 more
doaj   +2 more sources

Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Literature Review

Antibiotics, 2022
Lyme disease and associated co-infections are increasing worldwide and approximately 20% of individuals develop chronic Lyme disease (CLD)/Post-Treatment Lyme Disease Syndrome (PTLDS) despite early antibiotics.
Richard I Horowitz, Phyllis R Freeman
exaly   +3 more sources

Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies [PDF]

Blood Advances
: Monomorphic posttransplant lymphoproliferative disorders (PTLDs) beyond diffuse large B-cell lymphoma (DLBCL) are rare, biologically heterogeneous entities with limited prospective data to guide treatment.
Suheil Albert Atallah-Yunes, Arushi Khurana, Thomas M. Habermann   +2 more
doaj   +2 more sources

Protein biomarker profiles in serum and CSF in 158 patients with PTLDS or persistent symptoms after presumed tick-bite exposure compared to those in patients with confirmed acute neuroborreliosis

PLoS ONE, 2022
BackgroundCurrent diagnostics for patients with lingering symptoms categorized as post-treatment Lyme disease syndrome (PTLDS) have their limitations and may be difficult to interpret.
K Nilsson, Andreas Mårtensson, Björn Olsen   +2 more
exaly   +2 more sources

A comparison of genome-wide association analyses of persistent symptoms after Lyme disease, fibromyalgia, and myalgic encephalomyelitis – chronic fatigue syndrome [PDF]

BMC Infectious Diseases
Background Up to 20% of Lyme disease cases experience post-treatment Lyme disease syndrome (PTLDS). The biological basis for PTLDS is poorly understood and no evidence-based treatment has been identified.
Annemarie G. Hirsch, Anne E. Justice, Amy Poissant, Cara M. Nordberg, Navya S. Josyula, John Aucott, Alison W. Rebman, Brian S. Schwartz   +7 more
doaj   +2 more sources

Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review

Antibiotics, 2020
Three patients with multi-year histories of relapsing and remitting Lyme disease and associated co-infections despite extended antibiotic therapy were each given double-dose dapsone combination therapy (DDD CT) for a total of 7–8 weeks. At the completion
Richard I Horowitz, Phyllis R Freeman
exaly   +3 more sources

HLA and pathogens in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and other post-infection conditions [PDF]

Scientific Reports
Viral infections have been widely implicated in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) pathogenesis. Recent evidence has also identified certain Human Leukocyte Antigen (HLA) alleles that are significantly associated with ME/CFS risk/
Apostolos P. Georgopoulos, Lisa M. James, Philip K. Peterson   +2 more
doaj   +2 more sources

Pre-existing oncohematological disease in kidney transplant recipients: impact on graft survival, acute rejection, and long-term clinical outcomes [PDF]

Frontiers in Immunology
IntroductionOncohematological disorders are heterogeneous conditions that present significant challenges in management prior to transplantation. Data about rejection risk, disease recurrence, eligibility criteria, and requested remission time before ...
Alberto Mella, Alberto Mella, Roberta Clari, Roberta Clari, Valeria Deiana, Valeria Deiana, Roberta Giraudi, Roberta Giraudi, Gloria Giovinazzo, Gloria Giovinazzo, Ester Gallo, Ester Gallo, Caterina Dolla, Caterina Dolla, Antonio Lavacca, Antonio Lavacca, Ana Maria Manzione, Ana Maria Manzione, Fabrizio Fop, Fabrizio Fop, Anna Allesina, Anna Allesina, Federica Cavallo, Sara Bringhen, Dario Ferrero, Roberto Mina, Corrado Tarella, Corrado Tarella, Benedetto Bruno, Filippo Mariano, Filippo Mariano, Luigi Biancone, Luigi Biancone   +32 more
doaj   +2 more sources

Current and emerging approaches for eliminating Borrelia burgdorferi and alleviating persistent Lyme disease symptoms [PDF]

Frontiers in Microbiology
Lyme disease is the most prevalent tick-borne infection caused by Borrelia burgdorferi bacteria in North America. Other Borrelia species are predominately the cause of this disease in Eurasia with some distinct and various overlapping manifestations ...
Kashaf Zafar, Onyedikachi C. Azuama, Nikhat Parveen   +2 more
doaj   +2 more sources